Growth Niches in the U.S. Peripheral Vascular Device Market are becoming more important than ever for MedTech teams. Devices like stents, catheters, guidewires, and embolization systems are central to treating conditions such as atherosclerosis and peripheral arterial disease (PAD).
But not every segment of this market is moving in the same direction. Some device categories are growing steadily, while others are stagnating or facing commoditization.
This blog explores how to identify those niches, why they matter, and what market dynamics are reshaping the landscape in 2026.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Why growth niches matter in the U.S. peripheral vascular device market
➜ What procedure trends are shaping new opportunities?
➜ Where competitors are strong and where they’re exposed
➜ How to use market data to find your niche
➜ Finding the signal in the noise
Key Takeaways
- The U.S. peripheral vascular device market includes stents, catheters, guidewires, and embolization systems used in conditions such as PAD and atherosclerosis.
- Growth is uneven: guidewires are expanding at over 7% CAGR, peripheral embolization at nearly 5% CAGR, while catheters and coils grow slowly at ~2% CAGR.
- Medtronic dominates stents and embolics, Stryker leads coils and guidewires, and Terumo tops catheters, but each faces vulnerabilities in faster-growing categories.
- Outpatient and ASC migration is reshaping buying priorities, making cost-effectiveness and efficiency more important than ever.
- Using market data to align portfolios with faster-growing, less-crowded segments is key to spotting niches and building a competitive strategy.
Why growth niches matter in the U.S. peripheral vascular device market
Not all parts of the peripheral vascular market grow at the same pace.
For example, peripheral embolization devices are expanding at nearly 5% CAGR, supported by increased PAD procedures and their migration into outpatient and ASC settings.
On the other hand, catheters are growing at around 2% CAGR, showing signs of maturity and tighter price competition.
Guidewires, meanwhile, are among the fastest-growing categories, at over 7% CAGR, offering a bright spot for companies positioned in this segment.
These differences create clear painpoints and opportunities:
- Companies heavily invested in catheters face margin pressure as hospitals and ASCs see them as interchangeable.
- Players with strong embolization portfolios are well positioned to ride outpatient demand.
- Guidewires represent one of the few true growth engines, but only a handful of companies hold meaningful share here.
👉 Unlock Cardiovascular Devices Market Insights
What procedure trends are shaping new opportunities?
One of the biggest shifts in 2026 is where procedures are performed.
While hospitals remain central to vascular interventions, more high-volume PAD and embolization procedures are moving to outpatient and ambulatory surgical centers (ASCs).
This has two major impacts:
- Product design and procurement priorities are changing. ASCs often look for cost-effective devices and standardized kits that simplify workflows.
- New buyers are entering the market. Manufacturers must now address ASC administrators as much as hospital procurement teams.
For device companies, this migration means rethinking sales strategies.
Products that emphasize ease of use, predictable outcomes, and total cost savings are more likely to succeed in this setting.
Where competitors are strong and where they’re exposed
Market leaders dominate in some categories but remain vulnerable in others.
- Medtronic leads in stents and embolics but has almost no share in guidewires.
- Stryker controls much of the guidewire and coil market but has no embolics in its portfolio.
- Terumo holds the largest share of catheters but is overexposed to a segment growing at only ~2% CAGR.
- Boston Scientific and Sirtex are leaders in peripheral embolization, where growth is stronger, but face rising competition from mid-size players.
This uneven positioning creates opportunities for challengers.
A company that identifies where leaders are weak, for example, guidewires for Medtronic or embolics for Stryker, can carve out competitive share with the right portfolio strategy.
How to use market data to find your niche
Spotting niches is about combining three key signals:
- Growth rate: Is the segment expanding faster than the average?
- Competitor share: Is the market concentrated, or are there gaps where challengers can win?
- Procedure adoption: Are volumes rising, stable, or declining?
For example, peripheral embolization is growing at ~5% CAGR, driven by PAD procedures in ASCs. Combine that with Boston Scientific’s leadership position and Sirtex’s strong share, and it’s clear this market is competitive but not closed, especially for companies that can serve outpatient centers with cost-effective solutions.
👉 The U.S. Peripheral Vascular Device Market Report 2025 provides full procedure data, competitor shares, and forecasts across every major segment, giving MedTech teams the clarity to target the right niches.
Finding the signal in the noise
The U.S. peripheral vascular device market is full of both promise and pressure.
Catheters and coils are slowing down, guidewires and embolization are gaining speed, and procedure migration is reshaping how products are purchased.
For manufacturers, resellers, and investors, the winners will be those who look beyond the top-line market size and focus on where growth and opportunity align.
With reliable data on segment growth, competitor positions, and procedure adoption, finding the right niche is not just possible, it’s practical.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
